NERV

Minerva Neurosciences, Inc. [NERV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NERV Stock Summary

Top 10 Correlated ETFs

NERV


Top 10 Correlated Stocks

NERV


In the News

08:14 29 Mar 2024 NERV

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.

04:05 29 Mar 2024 NERV

Minerva Neurosciences: There's Probably Time For One More Rally

Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for schizophrenia, albeit for cognitive impairments associated with schizophrenia. NERV has six months until the PDUFA goal date for its roluperidone application but used only $4M in cash in operating activities in Q2, so cash isn't currently a concern.

10:57 29 Mar 2024 NERV

Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

02:11 29 Mar 2024 NERV

Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

05:34 29 Mar 2024 NERV

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage.

01:02 29 Mar 2024 NERV

What Makes Minerva Neurosciences (NERV) a New Buy Stock

Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

08:30 29 Mar 2024 NERV

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023.

11:31 29 Mar 2024 NERV

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day, and thank you for standing by.

08:30 29 Mar 2024 NERV

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Management to Host Conference Call Management to Host Conference Call

12:02 29 Mar 2024 NERV

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

NERV Financial details

Company Rating
Neutral
Market Cap
18.67M
Income
-26.63M
Revenue
0
Book val./share
-3.76
Cash/share
5.42
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-2.11
Forward P/E
-0.57
PEG
0.47
P/S
-
P/B
-2.74
P/C
0.48
P/FCF
-3.38
Quick Ratio
14
Current Ratio
14.4
Debt / Equity
-2.88
LT Debt / Equity
-2.88
-
-
EPS (TTM)
-4.01
EPS next Y
-4.54
EPS next Q
-1.2
EPS this Y
-36.85%
EPS next Y
13.22%
EPS next 5Y
-122.44%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
15.53%
-
-
-
-
SMA20
-25%
SMA50
-57.14%
SMA100
-40%
Inst Own
40.13%
Inst Trans
0.91%
ROA
-41%
ROE
131%
ROC
-0.35%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
6.99M
Shs Float
5.44M
-
-
-
-
Target Price
-
52W Range
1.58-13.49
52W High
-80.15%
52W Low
+158%
RSI
31
Rel Volume
0.22
Avg Volume
128.3K
Volume
28.23K
Perf Week
-0.39%
Perf Month
-69.25%
Perf Quarter
-60.31%
Perf Half Y
-64.85%
-
-
-
-
Beta
0.212
-
-
Volatility
0.05%, 1.91%
Prev Close
0%
Price
2.58
Change
2.79%

NERV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
08.07000
Net income per share
-14.80.38-9.35-7.3-4.61
Operating cash flow per share
-8.91-6.63-4.61-4.62-2.27
Free cash flow per share
-8.91-6.63-4.61-4.62-2.27
Cash per share
9.44.9711.386.766.3
Book value per share
5.710.321.49-3.75-4.37
Tangible book value per share
-0.474.43-1.3-6.54-6.66
Share holders equity per share
5.710.321.49-3.75-4.37
Interest debt per share
0.060.021.1815.1913.88
Market cap
277.39M95.53M34.23M8.49M40.01M
Enterprise value
256.26M70.28M-26.52M46.13M81.02M
P/E ratio
-3.8449.22-0.69-0.22-1.33
Price to sales ratio
02.32000
POCF ratio
-6.39-2.82-1.39-0.34-2.71
PFCF ratio
-6.39-2.82-1.39-0.34-2.71
P/B Ratio
9.991.814.29-0.42-1.41
PTB ratio
9.991.814.29-0.42-1.41
EV to sales
01.71000
Enterprise value over EBITDA
-3.3836.440.59-1.83-3.51
EV to operating cash flow
-5.9-2.081.08-1.87-5.48
EV to free cash flow
-5.9-2.081.08-1.87-5.48
Earnings yield
-0.260.02-1.46-4.59-0.75
Free cash flow yield
-0.16-0.35-0.72-2.9-0.37
Debt to equity
0.0100-3.68-2.88
Debt to assets
0001.341.44
Net debt to EBITDA
0.28-13.091.34-1.49-1.78
Current ratio
7.118.6822.0729.1512.57
Interest coverage
00-7.17-3.41-2.79
Income quality
0.6-17.430.490.770.49
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.42000
Research and developement to revenue
00.54000
Intangibles to total assets
0.390.520.190.270.26
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
000-1.920
Stock based compensation to revenue
00.24000
Graham number
43.569.417.7224.8221.3
ROIC
-2.60.04-5.49-0.57-0.43
Return on tangible assets
-1.520.07-0.8-0.97-0.71
Graham Net
-0.794-1.57-7.15-6.82
Working capital
40.51M24.28M59.38M38.78M38.66M
Tangible asset value
-2.29M22.59M-6.94M-34.94M-43.34M
Net current asset value
-2.58M22.48M-6.94M-34.95M-43.36M
Invested capital
0.0100-3.68-2.88
Average receivables
0001.56M1.56M
Average payables
2.06M1.66M1.42M1.41M1.39M
Average inventory
000-1.51M-1.51M
Days sales outstanding
00000
Days payables outstanding
5.24K06.65K41.58K21.27K
Days of inventory on hand
000-129.37K0
Receivables turnover
00000
Payables turnover
0.0700.050.010.02
Inventory turnover
00000
ROE
-2.60.04-6.261.951.05
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.57-0.67-1.12-1.03-1.19
Operating cash flow per share
-0.77-0.02-0.7-0.91-0.79
Free cash flow per share
-0.77-0.02-0.7-0.91-0.79
Cash per share
6.766.749.46.25.42
Book value per share
-3.75-4.98-2.27-2.65-3.76
Tangible book value per share
-6.54-7.78-4.97-4.62-5.73
Share holders equity per share
-3.75-4.98-2.27-2.65-3.76
Interest debt per share
14.1714.5514.4710.2711.13
Market cap
8.49M8.54M50.37M52.23M46.55M
Enterprise value
46.13M48.28M76.32M85.15M87.55M
P/E ratio
-0.25-0.59-2.03-1.67-1.29
Price to sales ratio
00000
POCF ratio
-2.07-74.04-13.01-7.57-7.77
PFCF ratio
-2.06-74.04-13.01-7.57-7.77
P/B Ratio
-0.42-0.32-4.03-2.61-1.64
PTB ratio
-0.42-0.32-4.03-2.61-1.64
EV to sales
00000
Enterprise value over EBITDA
-9.11-9.04-16.91-14.01-12.22
EV to operating cash flow
-11.22-418.32-19.71-12.34-14.61
EV to free cash flow
-11.22-418.32-19.71-12.34-14.61
Earnings yield
-0.99-0.42-0.12-0.15-0.19
Free cash flow yield
-0.48-0.01-0.08-0.13-0.13
Debt to equity
-3.68-2.84-6.21-3.98-2.88
Debt to assets
1.341.471.161.261.44
Net debt to EBITDA
-7.43-7.44-5.75-5.42-5.72
Current ratio
29.1514.6627.3714.412.57
Interest coverage
-2.63-2.7-2.232.92-3.27
Income quality
0.610.020.6310.66
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.270.290.220.240.26
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.330000
Stock based compensation to revenue
00000
Graham number
11.518.697.587.8510.04
ROIC
-0.12-0.17-0.09-0.1-0.05
Return on tangible assets
-0.21-0.1-0.12-0.16-0.21
Graham Net
-7.15-7.91-5.05-4.79-5.86
Working capital
38.78M34.17M50.32M44.88M38.66M
Tangible asset value
-34.94M-41.52M-27.41M-34.92M-43.34M
Net current asset value
-34.95M-41.54M-27.42M-34.95M-43.36M
Invested capital
-3.68-2.84-6.21-3.98-2.88
Average receivables
1.56M1.56M000
Average payables
751.28K965.33K629.62K846.66K1.6M
Average inventory
-1.51M-1.51M000
Days sales outstanding
00000
Days payables outstanding
13.67K11.17K3.47K16.21K20.98K
Days of inventory on hand
-42.53K0000
Receivables turnover
00000
Payables turnover
0.010.010.030.010
Inventory turnover
00000
ROE
0.420.140.490.390.32
Capex per share
00000

NERV Frequently Asked Questions

What is Minerva Neurosciences, Inc. stock symbol ?

Minerva Neurosciences, Inc. is a US stock , located in Waltham of Ma and trading under the symbol NERV

What is Minerva Neurosciences, Inc. stock quote today ?

Minerva Neurosciences, Inc. stock price is $2.58 today.

Is Minerva Neurosciences, Inc. stock public?

Yes, Minerva Neurosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap